May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
A Prospective Comparative Switch Study From Xalacom (Timolol 0.5% + Latanoprost 0.005%) to Lumigan (Bimatoprost 0.03%)
Author Affiliations & Notes
  • R. Saxena
    Ophthalmology, Kettering General Hospital, Kettering, United Kingdom
  • C. Brittain
    Ophthalmology, Luton and Dunstable Hospital, Luton, United Kingdom
  • A. Waldock
    Ophthalmology, Luton and Dunstable Hospital, Luton, United Kingdom
  • Footnotes
    Commercial Relationships  R. Saxena, None; C. Brittain, None; A. Waldock, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 2453. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. Saxena, C. Brittain, A. Waldock; A Prospective Comparative Switch Study From Xalacom (Timolol 0.5% + Latanoprost 0.005%) to Lumigan (Bimatoprost 0.03%) . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2453.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To compare intraocular pressure control in Glaucoma patients on switching from Xalacom to Bimatoprost 0.03% and to evaluate any changes in respiratory function, heart rate and the incidence of ocular side effects. Methods: 50 consecutive primary open angle glaucoma patients who had been on topical Xalacom monotherapy for at least 2 months were recruited. They underwent a full ocular examination and answered a questionnaire on ocular symptoms. Their respiratory function was assessed using a portable microelectronic spirometer and pulse recorded. The topical medication was switched to Bimatoprost and the patients were reviewed in an identical manner two months later. Results: There was no significant difference in mean IOP between Xalacom (17.2mmHg) and Bimatoprost (16.4mmHg) (paired t–test p=0.23). The mean heart rate was 70beats per minute on Xalacom and increased to 76beats per minute on Bimatoprost (paired t–test, p=0.01). The mean peak expiratory flow rate (PEFR) was 328l/min on Xalacom, but increased to 346l/min on Bimatoprost (p=0.04). The mean FEV1/FVC ratio increased from 76.6 to 80.1 when changed from Xalacom to Bimatoprost (p=0.03). Symptoms of redness, blurred vision, stinging and watering were similar for Xalacom and Bimatoprost. However patients demonstrating hyperaemia doubled to 22 when switched to Bimatoprost. Conclusions: Bimatoprost alone is as efficacious as Xalacom in lowering IOP and has less effect on cardiorespiratory function. This study indicates that bimatoprost is a very safe, well–tolerated and efficacious IOP lowering agent.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled • intraocular pressure • clinical (human) or epidemiologic studies: outcomes/complications 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.